Self-expanding Mesh Stent for Esophageal Cancer Stenosis

Domschke, W; Ec, Foerster; Matek, W; Rödl, W

doi:10.1055/s-2007-1012818

Cited by 121 publications

(45 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 1983, Frimberger first reported the use of metallic stent to treat esophageal stenosis [46] . Domschke in 1990 successfully used self-expansible woven mesh type metallic stent to treat a case of esophageal malignant obstruction [47] . Thus it was made possible the relief of obstruction of digestive tract by non-surgical procedures.…”

Section: Significance and Technical Difficultiesmentioning

confidence: 99%

Treatment of malignant digestive tract obstruction by combined intraluminal stent installation and intra-arterial drug infusion

Mao¹

2001

WJG

View full text Add to dashboard Cite

AIM To study the palliative treatment of malignant obstrution of digestive tract with placement of intraluminal stent combined with intra-arterial infusion of chemotherapeutic drugs.METHODS A total of 281 cases of digestive tract malignant obstruction were given per oral (esophagus, stomach, duodenum and jejunum), per anal (colon and rectum) and percutaneous transhepatic (biliary) installation of metallic stent. Among them, 203 cases received drug infusion by cannulation of tumor supplying artery with Seldinger's technique. RESULTSAltogether 350 stents were installed in 281 cases, obstructive symptoms were relieved or ameliorated after installation. Occurrence of restenotic obstruction was 8-43 weeks among those with intraarterial drug infusion, which was later than 4-26 weeks in the group with only stent installation. The average survival time of the former group was 43 (3-105) weeks, which was significantly longer than 13 (3-24) weeks of the latter group.CONCLUSION Intraluminal placement of stent combined with intra-arterial infusion chemotherapy is one of the effective palliative therapies for malignant obstruction of the digestive tract with symptomatic as well as etiological treatment.

show abstract

Section: Significance and Technical Difficultiesmentioning

confidence: 99%

Treatment of malignant digestive tract obstruction by combined intraluminal stent installation and intra-arterial drug infusion

Mao¹

2001

WJG

View full text Add to dashboard Cite

show abstract

“…Since Domschke et al [1] reported the first successful treatment of malignant esophageal strictures with an uncovered expandable metal stent in 1990, placement of covered or uncovered or antireflux covered expandable UGIT metal stents has been shown to be a safe, easy, and effective treatment for malignant UGIT strictures. Cwikiel et al [2] reported the first successful treatment of benign esophageal strictures in 1993.…”

Section: Discussionmentioning

confidence: 99%

Follow-up evaluation for benign stricture of upper gastrointestinal tract with stent insertion

Cheng¹,

Li²,

Chen³

et al. 2003

WJG

View full text Add to dashboard Cite

AIM:To determine the best mothod for benign stricture of the upper gastrointestinal tract (UGIT) with stent insertion by follow-up evaluation. METHODS:A total of 110 stents insertions were performed in 110 cases of benign stricture of the UGIT. Permanent (group A) and temporary (group B) placement of an expandable metal stent in 30 cases and 80 cases respectively. All cases were completed under fluoroscopy. RESULTS:In group A, 30 uncovered or antireflux covered or partially covered expandable metal stents were placed permanently. In group A, 5 cases (16.7 %) in 3-months, 5 cases (20.0 %) in 6-months, 6 cases (25 %) in the 1 st year, 6 cases (50 %) in the 3 rd year, and 4 cases (80 %) in the 5 th year exhibited dysphagia relapse. In group B, a partiallycovered expandable metal stent was temporarily placed in each patient and removed after 3-7 days via gastroscopy. Follow-up data in this group showed that 8 cases (7.5 %) in 3-months, 9 cases (12.0 %) in 6-months,10 cases (15. CONCLUSION:The best mothod for benign stricture of UGIT with stent insertion is temporary placement of a partially-covered expandable metal stent.Cheng YS, Li MH, Chen WX, Zhuang QX, Chen NW, Shang KZ. Follow-up evaluation for benign stricture of upper gastrointestinal tract with stent insertion.

show abstract

“…Atkinson and Ferguson [26] treated inoperable malignant strictures at the cardia with fiberoptic endoscopy in 1977, and Frimberger [27] treated malignant esophageal stenoses with an expanding spiral in 1983. Later, nickel titanium alloy, stainless steel and other metal stents have been developed in recent decades [28]. The types and classifications of esophageal stents are various.…”

Section: Stent Placementmentioning

confidence: 99%

Interventional Therapy of Esophageal Cancer

Mao

2016

Gastrointest Tumors

View full text Add to dashboard Cite

Esophageal cancer (EC) is the fourth leading cause of cancer death in China. Despite a lot of advances in diagnosis and therapy, the survival rate of patients with EC is low. There is urgent need for a variety of methods and techniques to improve the survival time and alleviate the lesions of EC. Nowadays, alternative and less invasive approaches to the treatment of ECs are being identified. Here, we review several main interventional methods at different stages of EC, including endoscopic resection, stent placement, arterial infusion, photodynamic therapy, and radiofrequency ablation. This review will focus on the indications, methods, clinical outcomes, and complications of these methods, which may help guide the way forward.

show abstract

Self-expanding Mesh Stent for Esophageal Cancer Stenosis

Cited by 121 publications

References 0 publications

Treatment of malignant digestive tract obstruction by combined intraluminal stent installation and intra-arterial drug infusion

Treatment of malignant digestive tract obstruction by combined intraluminal stent installation and intra-arterial drug infusion

Follow-up evaluation for benign stricture of upper gastrointestinal tract with stent insertion

Interventional Therapy of Esophageal Cancer

Contact Info

Product

Resources

About